Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GHRS
SELLGH Research PLC · Healthcare · Ireland · $1.9B · Avg Vol: $8M/d
COMPANY DESCRIPTION
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to developing novel psychedelic-derived therapies for psychiatric and neurological disorders. The company positions itself as an early innovator in a potentially transformative therapeutic space, focusing on proprietary drug candidates. Its pipeline targets conditions with significant unmet medical needs, presenting a high-growth opportunity in a specialized healthcare niche.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.43 | -0.68 | -0.75 | -0.79 | — | -0.87 | -1.40 | -2.00 | — |
| Shares | 52.0M | 52.0M | 52.0M | 62.0M | +19.2% | 68.6M | — | — | — |
| Debt | 0 | 1.0M | 0.6M | 0.5M | -27.5% | 0.4M | — | — | — |
| Equity | 249.8M | 219.0M | 179.0M | 279.7M | 3.8% | — | — | — | — |
| Op CF | -26.2M | -33.3M | -42.3M | -43.6M | — | -45.6M | — | — | — |
| Inv CF | -84.7M | -54.1M | 65.1M | 46.2M | — | — | — | — | — |
| Fin CF | 0 | -0.2M | -0.3M | 139.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GHRS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GHRS | GH Research PLC(you) | $1.9B | 34 | SELL |
| PRTA | Prothena Corporation plc | $458M | 27 | SELL |
| JAZZ | Jazz Pharmaceuticals plc | $15.9B | 88 | STRONG BUY |
| 0RGI.L | Cosmo Pharmaceuticals N.V. | $1.8B | 16 | STRONG SELL |
| COPN.SW | Cosmo N.V. | $1.4B | 19 | STRONG SELL |
| PRGO | Perrigo Company plc | $1.4B | 49 | HOLD |
| UPR.L | Uniphar plc | $1.4B | 65 | HOLD |
| AMRN | Amarin Corporation plc | $284M | 44 | HOLD |
| ALKS | Alkermes plc | $8.8B | 78 | BUY |
| 2M6.DE | Medtronic plc | $104.4B | 72 | BUY |
Peer medians: ROE 1.8% · P/E 23.4x · Gross margin 48.5%